Survey in pediatric ICU to reduce upfront vancomycin use
Part of Infections clinical trials.
This study is a survey and quality-improvement effort in participating children’s intensive care units. It aims to understand and change how doctors decide to start vancomycin (an antibiotic) when sepsis is suspected, to improve care and avoid unnecessary use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (the patient) must be admitted to a participating pediatric ICU during the study time period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a different way of giving vancomycin to children with sepsis to reduce the risk of kidney injury. It compares standard dosing to an approach that adjusts dose based on how the kidneys are working.
This trial tests a computer tool to help doctors choose the right antibiotic for sepsis early on. It may help improve treatment by providing personalized recommendations based on your condition.
This trial compares giving a long, continuous infusion versus standard short infusions of certain antibiotics (beta-lactams) to children with sepsis in intensive care. The goal is to find which method works better and is safer.
This study watches how safely two common antibiotics (vancomycin and a combination called piperacillin/tazobactam) work together in hospitalized patients with serious infections. Researchers want to make sure the combination doesn't harm kidney function.
This trial checks if giving higher doses of beta-lactam antibiotics (a type of strong antibiotic) right from the start helps people in the ICU with septic shock. It aims to find the best dose to fight the infection quickly.
This study asks NICUs to reduce the use of the antibiotic vancomycin. It's for hospital units that are part of certain networks and agree to follow the study plan.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.